Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Sees Significant Increase in Short Interest

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 40,400 shares, a growth of 124.4% from the January 15th total of 18,000 shares. Approximately 2.4% of the company’s stock are short sold. Based on an average daily volume of 47,100 shares, the short-interest ratio is currently 0.9 days.

Hedge Funds Weigh In On Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Geode Capital Management LLC purchased a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 10,308 shares of the company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned about 0.59% of Creative Medical Technology as of its most recent SEC filing. 1.42% of the stock is currently owned by institutional investors and hedge funds.

Creative Medical Technology Stock Up 16.0 %

Shares of CELZ traded up $0.66 during trading hours on Thursday, reaching $4.79. The company’s stock had a trading volume of 378,170 shares, compared to its average volume of 75,108. The firm has a market cap of $8.38 million, a price-to-earnings ratio of -1.25 and a beta of 1.85. Creative Medical Technology has a 1-year low of $1.96 and a 1-year high of $10.28. The company has a 50 day moving average of $2.62 and a two-hundred day moving average of $3.06.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.